• PN: B113369

COMPONENTS

45x Ab-conjugated beads (S5P8 - human TRAIL-R3 Ab-bead). PN: B113369A. One vial containing 100 µL of anti-human sTRAIL-R3 conjugated to AimPlex Bead S5P8.

25x Biotin-detection Ab (human sTRAIL-R3 Biotin-dAb). PN: B113369B. One vial containing 100 µL of biotinylated anti-human sTRAIL-R3.

Lyophilized Standard Mix-Human Group 5 Panel A, 8-Plex. PN: HG50008. One vial containing lyophilized recombinant human sE-Cadherin, sLIGHT, sTRAIL-R3, s4-1BB, sCD30L, sVEGFR2, BlyS, and sPECAM-1. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

STORAGE:  2-8 C in the dark.

IMPORTANT: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

APPLICATION: Optimal antibody pair and antigen standard for assaying human TNFRSF10C/sCD263/sTRAIL-R3. Can be multiplexed with other analytes in Human Group 5.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

Sensitivity (LOD): < 5 pg/mL

Quantitation range:

LLOQ: < 10 pg/mL

ULOQ: > 5,000 pg/mL

Standard dose recovery: 70-130%

Intra-assay CV: < 10%

Inter-assay CV: < 20%

Cross-reactivity of analytes in Human Group 5: Negligible

Sample volume: 15 µL/test

Description:

TRAIL receptor 3 (TRAIL-R3), also known as tumor necrosis factor receptor superfamily member 10C (TNFRSF10C) and CD263, is a human cell surface receptor of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain and a transmembrane domain, but no cytoplasmic death domain. This receptor is not capable of inducing apoptosis, and is thought to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis. This gene was found to be a p53-regulated DNA damage-inducible gene. The expression of this gene was detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL. Diseases associated with TNFRSF10C include pancreatic cancer and prostate cancer.

References:

1.      Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, Goodwin RG, Smith CA (Nov 1997). "Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family". J Exp Med 186 (7): 1165–70. doi:10.1084/jem.186.7.1165. PMC 2199077. PMID 9314565.

2.      MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES (Nov 1997). "Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL". J Biol Chem. 272 (41): 25417–20. doi:10.1074/jbc.272.41.25417. PMID 9325248.